Dimension Therapeutics (DMTX) Tops Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results
May 12, 2016 9:03 AM EDTExpanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease
Expect to file INDs for lead IMD product candidates, DTX301 for OTC deficiency and DTX401 for GSDIa, both in second half 2016; Initiate dosing for DTX301 for OTC deficiency in second half 2016
Ongoing Phase 1/2 trial of DTX101 for hemophilia B on plan to report initial data in 2H 2016
CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ: DMTX), a biopharmaceutical company advancing novel,... More
